Deqi Pharmaceuticals: Voluntarily announces that it has received a down payment of 60 million US dollars for the ATG-201.

Deqi Pharmaceuticals announced that it has received a $60 million advance payment from UCB () for the ATG-201 milestone agreement. Receiving this advance payment under the milestone agreement with UCB further strengthens the Group's cash position and provides strong financial support to advance the Group's innovative drug pipeline and accelerate access to more patients.